Clinical trials: Peritoneal Malignancies
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
- Trial name
- DENALI (NCT05128825)
- Testing
- azenosertib
- Where
- 89 sites in United States, Australia and 7 more
- Volunteers
- 310 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Ovarian Cancer
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- OVATION-3 (NCT06915025)
- Testing
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin
- Where
- 10 sites in United States
- Volunteers
- 500 people
- Sponsor
- Imunon
Ovarian Cancer, Peritoneal Cancer
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07743164
- Testing
- R-DXd, Bevacizumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 646 people
- Sponsor
- Merck Sharp & Dohme LLC
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis.
- Conditions
- Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer
- Trial name
- NCT04847063
- Testing
- Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product.
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05617755
- Testing
- AB-1015
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arsenal Biosciences, Inc.
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis
Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma
This study is a prospective, multicenter, open-label, exploratory phase II clinical trial aimed at evaluating the efficacy and safety of serplulimab combined with DOS, lenvatinib, and PIPACS in patients with oligometastatic…
- Trial name
- NCT07902648
- Testing
- Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC
- Volunteers
- 42 people
- Sponsor
- Fujian Cancer Hospital
Ovarian Cancer, Fallopian Tube Cancer
BEACON - ABC in Recurrent Platinum Resistant HGSOC
Epithelial ovarian cancer (EOC) is the ninth most common cause of cancer in Australian women, with an estimated 1500 new diagnoses in Australia in 2015, and remains the seventh most common cause of cancer death in Australian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- BEACON (NCT03363867)
- Testing
- Atezolizumab, Bevacizumab, Cobimetinib
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Ovary Cancer, Fallopian Tube Cancer
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic…
- Conditions
- Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT06617923
- Testing
- Senaparib, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hyperthermic Intraperitoneal Chemotherap, Colorectal Cancer Metastatic
Cost-utility Evaluation of Cytoreductive Surgery With or Without Mitomycin-C Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Resectable Colorectal Peritoneal Metastases
Colorectal cancer is the second leading cause of cancer death in France, with close to 50,000 new cases each year. About half of the patients develop liver, lung and/or peritoneal metastases during the course of the…
- Conditions
- Hyperthermic Intraperitoneal Chemotherap, Colorectal Cancer Metastatic, Peritoneal Metastases, Cytoreductive Surgery
- Trial name
- ECO-CHIP (NCT07901075)
- Volunteers
- 398 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer Female, Ovarian Cancer
Diet, Hepcidin, and Chemotherapy RDI
This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer…
- Conditions
- Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06483997
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- George Washington University
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm.
- Conditions
- Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer, Platinum-Resistant FRα-Positive Peritoneal Cancer
- Trial name
- MIRELA (NCT07896421)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- AbbVie
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal…
- Conditions
- FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01970722
- Testing
- Carboplatin, Cisplatin, Gemcitabine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Trial name
- NCT02839707
- Testing
- Atezolizumab, Bevacizumab, Computed Tomography
- Where
- 919 sites in United States, Puerto Rico
- Volunteers
- 444 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Malignant Mesothelioma
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma.
- Trial name
- NCT05001880
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal (Metastatic) Cancer, Colorectal Cancer
Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study
his prospective, single-center observational pilot study evaluates whether peritoneal histopathological growth patterns can be assessed on limited excisional biopsies obtained during staging laparoscopy in adults with suspected…
- Conditions
- Peritoneal (Metastatic) Cancer, Colorectal Cancer, Colorectal (Colon or Rectal) Cancer, Histopathological Growth Patterns (HGPs)
- Trial name
- PROCPHGP (NCT07474025)
- Where
- 2 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- Jules Bordet Institute
Ovarian Cancer, Fallopian Tube Cancer
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
- Trial name
- N-Plus (NCT05460000)
- Testing
- 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 640 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Ovarian Neoplasm Epithelial, Ovarian Cancer
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and…
- Conditions
- Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma
- Trial name
- NCT05605535
- Testing
- Oregovomab, Paclitaxel, Carboplatin
- Where
- 14 sites in India
- Volunteers
- 88 people
- Sponsor
- CanariaBio Inc.